Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 184,639 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 184,639 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 3.9%

SION traded up $1.72 during midday trading on Monday, hitting $45.95. The company had a trading volume of 670,726 shares, compared to its average volume of 474,065. Sionna Therapeutics, Inc. has a twelve month low of $11.77 and a twelve month high of $48.45. The firm’s 50-day simple moving average is $38.55 and its 200-day simple moving average is $39.36.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. As a group, equities analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SION. Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics during the 4th quarter worth $26,290,000. Vanguard Group Inc. lifted its stake in shares of Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp boosted its position in shares of Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the last quarter. Finally, Viking Global Investors LP grew its stake in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Citizens Jmp began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday. Guggenheim upped their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Finally, Wedbush initiated coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.